April 24th, 2022 (Earnings Report) Dear Reader, We just identified several healthtech stocks that are expected to release earnings this week. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
CVRx
Symbol: CVRX
Recent Price: $4.85
Average Analyst Price Target: $22.00 (353.61%)
Market Cap: $105.25M
Last Year's EPS: -$0.42
Consensus EPS Forecast: -$0.49
Expected Earnings Date: Apr 24 2022
Recent Analyst Action: Matthew O'Brien, analyst at Piper Sandler, reiterates coverage on CVRx (CVRX) in the Healthcare sector with a Buy rating and a price target of $ 20 (2 months ago).
TipRanks.com also reports that CVRx currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $22.00 . The target pricing ranges from a high forecast of $24.00 down to a low forecast of $20.00. CVRx (CVRX)’s last closing price was $4.85 which would put the average price target at 353.61% upside.Here are 3rd party ratings for CVRX:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 35% (165 out of 253)
--------------------------------------------------------------------------
Universal Health
Symbol: UHS
Recent Price: $132.93
Average Analyst Price Target: $163.67 (23.12%)
Market Cap: $9.90B
Last Year's EPS: $2.44
Consensus EPS Forecast: $2.47
Expected Earnings Date: Apr 24 2022
Recent Analyst Action: Ann Hynes, analyst at Mizuho Securities, reiterates coverage on Universal Health (UHS) in the Healthcare sector with a Buy rating and a price target of $ 290 (2 weeks ago).
TipRanks.com also reports that Universal Health currently has 10 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $163.67 . The target pricing ranges from a high forecast of $290.00 down to a low forecast of $134.00. Universal Health (UHS)’s last closing price was $132.93 which would put the average price target at 23.12% upside.Here are 3rd party ratings for UHS:
- TipRanks.com: Hold
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: hold
- Zacks.com: Hold, Top 38% (97 out of 253)
--------------------------------------------------------------------------
Ambrx Biopharma
Symbol: AMAM
Recent Price: $3.81
Average Analyst Price Target: $11.00 (188.71%)
Market Cap: $133.18M
Last Year's EPS: -$0.09
Consensus EPS Forecast: -$0.65
Expected Earnings Date: Apr 25 2022
Recent Analyst Action: Joel Beatty, analyst at Robert W. Baird, reiterates coverage on Ambrx Biopharma (AMAM) in the Healthcare sector with a Buy rating and a price target of $ 16 (2 weeks ago).
TipRanks.com also reports that Ambrx Biopharma currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $11.00 . The target pricing ranges from a high forecast of $16.00 down to a low forecast of $6.00. Ambrx Biopharma (AMAM)’s last closing price was $3.81 which would put the average price target at 188.71% upside.Here are 3rd party ratings for AMAM:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Bottom 45% (139 out of 253)
--------------------------------------------------------------------------
Centene
Symbol: CNC
Recent Price: $84.41
Average Analyst Price Target: $94.25 (11.66%)
Market Cap: $49.20B
Last Year's EPS: $1.63
Consensus EPS Forecast: $1.69
Expected Earnings Date: Apr 25 2022
Recent Analyst Action: David Windley, analyst at Jefferies, reiterates coverage on Centene (CNC) in the Healthcare sector with a Hold rating and a price target of $ 82 (1 month ago).
TipRanks.com also reports that Centene currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $94.25 . The target pricing ranges from a high forecast of $105.00 down to a low forecast of $82.00. Centene (CNC)’s last closing price was $84.41 which would put the average price target at 11.66% upside.Here are 3rd party ratings for CNC:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 32% (82 out of 253)
--------------------------------------------------------------------------
Chemed
Symbol: CHE
Recent Price: $490.6
Average Analyst Price Target: $579.00 (18.02%)
Market Cap: $7.34B
Last Year's EPS: $4.44
Consensus EPS Forecast: $4.47
Expected Earnings Date: Apr 25 2022
Recent Analyst Action: Ben Hendrix, analyst at RBC Capital, reiterates coverage on Chemed (CHE) in the Healthcare sector with a Buy rating and a price target of $ 579 (1 month ago).
TipRanks.com also reports that Chemed currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $579.00 . The target pricing ranges from a high forecast of $579.00 down to a low forecast of $579.00. Chemed (CHE)’s last closing price was $490.6 which would put the average price target at 18.02% upside.Here are 3rd party ratings for CHE:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 30% (178 out of 253)
--------------------------------------------------------------------------
Edwards Lifesciences
Symbol: EW
Recent Price: $118.38
Average Analyst Price Target: $130.25 (10.03%)
Market Cap: $73.55B
Last Year's EPS: $0.54
Consensus EPS Forecast: $0.57
Expected Earnings Date: Apr 25 2022
Recent Analyst Action: Richard Newitter, analyst at Truist Financial, reiterates coverage on Edwards Lifesciences (EW) in the Healthcare sector with a Buy rating and a price target of $ 145 (1 week ago).
TipRanks.com also reports that Edwards Lifesciences currently has 17 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $130.25 . The target pricing ranges from a high forecast of $145.00 down to a low forecast of $113.00. Edwards Lifesciences (EW)’s last closing price was $118.38 which would put the average price target at 10.03% upside.Here are 3rd party ratings for EW:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Bottom 35% (165 out of 253)
--------------------------------------------------------------------------
Exact Sciences
Symbol: EXAS
Recent Price: $60.68
Average Analyst Price Target: $100.91 (66.30%)
Market Cap: $10.57B
Last Year's EPS: -$0.18
Consensus EPS Forecast: -$1.1
Expected Earnings Date: Apr 25 2022
Recent Analyst Action: Unknown Analyst, analyst at Goldman Sachs, reiterates coverage on Exact Sciences (EXAS) in the Healthcare sector with a Buy rating and a price target of $ 85 (6 days ago).
TipRanks.com also reports that Exact Sciences currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $100.91 . The target pricing ranges from a high forecast of $155.00 down to a low forecast of $80.00. Exact Sciences (EXAS)’s last closing price was $60.68 which would put the average price target at 66.30% upside.Here are 3rd party ratings for EXAS:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 45% (139 out of 253)
--------------------------------------------------------------------------
Novartis
Symbol: NVS
Recent Price: $89.21
Average Analyst Price Target: n/a ()
Market Cap: $199.38B
Last Year's EPS: $1.52
Consensus EPS Forecast: $1.45
Expected Earnings Date: Apr 25 2022
Recent Analyst Action: Hans Engel, analyst at Erste Group, reiterates coverage on Novartis (NVS) in the Healthcare sector with a Buy rating and a price target of n/a (1 week ago).
TipRanks.com also reports that Novartis currently has n/a analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is n/a . The target pricing ranges from a high forecast of n/a down to a low forecast of n/a. Novartis (NVS)’s last closing price was $89.21 which would put the average price target at upside.Here are 3rd party ratings for NVS:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Sell, Top 32% (82 out of 253)
--------------------------------------------------------------------------
USANA Health
Symbol: USNA
Recent Price: $77.84
Average Analyst Price Target: $86.00 (10.48%)
Market Cap: $1.49B
Last Year's EPS: $1.45
Consensus EPS Forecast: $1.14
Expected Earnings Date: Apr 25 2022
Recent Analyst Action: Linda Bolton, analyst at D.A. Davidson, reiterates coverage on USANA Health (USNA) in the Healthcare sector with a Hold rating and a price target of $ 86 (1 week ago).
TipRanks.com also reports that USANA Health currently has 1 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $86.00 . The target pricing ranges from a high forecast of $86.00 down to a low forecast of $86.00. USANA Health (USNA)’s last closing price was $77.84 which would put the average price target at 10.48% upside.Here are 3rd party ratings for USNA:
- TipRanks.com: Hold
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 46% (136 out of 253)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com